Neuroendocrine carcinoma – Diagnostics

Go back

Neuroendocrine carcinoma is a type of cancer that starts in specialized cells found throughout the body, cells that combine traits of nerve cells and hormone-producing cells. Understanding how doctors identify and diagnose this uncommon condition is an important first step for anyone facing symptoms or concerns about their health.

Introduction: Who Should Undergo Diagnostics

Neuroendocrine carcinomas are rare cancers that can develop in many places throughout the body, most commonly in the digestive tract, lungs, and pancreas. Because these cancers start in cells that make hormones and respond to signals from the brain, they can affect many different body functions depending on where they are located and what hormones they produce.[1]

You should consider seeking medical evaluation if you experience persistent symptoms that don’t improve over time. These symptoms can be quite varied and often resemble less serious conditions, which is one reason why neuroendocrine carcinomas can be challenging to identify. Common warning signs include ongoing fatigue that doesn’t go away with rest, stomach pain that persists, diarrhea that continues for weeks, nausea and vomiting, shortness of breath, or coughing that sometimes produces blood.[2]

It’s important to remember that having these symptoms doesn’t necessarily mean you have cancer. Many other conditions can cause similar problems. However, if you notice symptoms that last for several weeks without improvement, or if they worsen over time, talking to a healthcare provider is advisable. Early diagnosis can make a significant difference in treatment outcomes.[3]

Certain people may need to be more vigilant about screening. If you have a family history of rare inherited conditions such as multiple endocrine neoplasia (a condition that causes overactive tumors to form in various organs and glands), your risk of developing neuroendocrine tumors increases. People with these genetic syndromes should discuss regular monitoring with their healthcare team even if they don’t have symptoms.[2]

⚠️ Important
Often, neuroendocrine tumors don’t cause symptoms until a tumor impacts an organ. This means the cancer may have been growing slowly in your body for years before you notice any problems. Don’t ignore persistent symptoms or write them off as just part of getting older. If something doesn’t feel right and symptoms continue for several weeks, seek medical attention.

Diagnostic Methods for Identifying Neuroendocrine Carcinoma

Diagnosing neuroendocrine carcinoma typically begins with a physical examination. Your healthcare provider will check your body for signs of cancer, such as swollen lymph nodes, and look for evidence that a tumor might be producing excess hormones. They will ask detailed questions about your symptoms, when they started, and how they’ve changed over time.[10]

Blood and Urine Tests

Blood and urine tests are often the next step in diagnosis. These tests look for signs of excess hormones that some neuroendocrine tumors produce. When neuroendocrine cells become cancerous, they sometimes make large amounts of hormones or similar substances that shouldn’t be present at high levels in your body. By measuring these substances in your blood or urine, doctors can get clues about whether a neuroendocrine tumor might be present and where it might be located.[10]

Blood tests can also reveal other important information, such as whether you’re anemic (have low red blood cells) or have elevated liver enzymes, which might indicate that the cancer has affected your liver. These findings can prompt doctors to investigate further with additional tests.[3]

Imaging Tests

Imaging tests create pictures of the inside of your body to help doctors see where tumors are located and how large they are. If there’s concern that cancer may have spread to other parts of the body, imaging tests can detect that as well. Several types of imaging may be used to diagnose neuroendocrine carcinoma.[10]

Ultrasound uses sound waves to create images of internal organs. It’s painless and doesn’t use radiation. Ultrasound can be particularly helpful for looking at organs like the liver or pancreas.[10]

A computed tomography scan, or CT scan, uses X-rays taken from many angles to create detailed, three-dimensional images of your body. The machine moves around you while you lie still on a table. CT scans can show tumors in many different parts of the body and help determine their size and location.[10]

Magnetic resonance imaging, or MRI, uses powerful magnets and radio waves instead of X-rays to create detailed images of your body’s soft tissues. This test can be especially useful for seeing certain types of tumors more clearly than other imaging methods.[10]

A specialized type of positron emission tomography scan, or PET scan, is particularly valuable for neuroendocrine tumors. This scan uses a radioactive tracer that attaches to cells with receptors for a chemical called somatostatin, which neuroendocrine tumor cells often have on their surface. The tracer contains a medicine called dotatate, so this kind of scan is also called a dotatate PET scan or somatostatin receptor PET scan. This test can find neuroendocrine tumors throughout the body, even small ones that other imaging tests might miss.[10]

Biopsy

A biopsy is the most definitive way to diagnose neuroendocrine carcinoma. During a biopsy, a small sample of tissue is removed from the suspected tumor and examined under a microscope in a laboratory. The laboratory tests can definitively show whether cancer cells are present and what type of cancer it is.[10]

How a biopsy is performed depends on where the tumor is located in your body. Some biopsies can be done with a needle inserted through the skin, guided by ultrasound or CT imaging. Others might require a more involved procedure, such as an endoscopy (where a flexible tube with a camera is inserted through your mouth or rectum) or even surgery to reach the tumor.[10]

Once the tissue sample is obtained, a specialist doctor called a pathologist examines the cells under a microscope. They look at how abnormal the cells appear and how quickly they are dividing and growing. This information helps determine whether the cancer is a neuroendocrine tumor that grows slowly or a neuroendocrine carcinoma that grows quickly. Neuroendocrine carcinomas look very different from normal neuroendocrine cells and are considered high-grade, fast-growing cancers.[6]

Distinguishing Between Tumor Types

It’s crucial for doctors to distinguish between different types of neuroendocrine cancers because they behave very differently and require different treatments. There are two main groups: neuroendocrine tumors, which can be slow, moderate, or fast growing, and neuroendocrine carcinomas, which are all fast growing. The cells in tumors still look somewhat similar to normal neuroendocrine cells, while the cells in carcinomas look very abnormal and not like normal cells at all.[6]

The pathologist assigns a grade to the cancer based on how the cells look and how fast they’re growing. Neuroendocrine tumors may be grade 1, 2, or 3. Neuroendocrine carcinomas are typically not assigned a grade because they are all considered high-grade by definition. Carcinomas may be described as small cell or large cell in appearance.[6]

⚠️ Important
Neuroendocrine tumors and neuroendocrine carcinomas are very different diseases, even though they start in the same type of cell. It’s essential to know which one you have because the treatment approaches and outcomes differ significantly. If you’re not sure which type you have, ask your doctor or specialist nurse to explain your diagnosis clearly.

Diagnostics for Clinical Trial Qualification

Clinical trials test new treatments for neuroendocrine carcinoma and often have specific requirements for which patients can participate. To determine if you qualify for a clinical trial, doctors use many of the same diagnostic tests described above, but they apply them with specific criteria in mind.[4]

Standard blood tests are typically required to ensure your organs, particularly your liver and kidneys, are functioning well enough to handle the experimental treatment being studied. Blood counts are checked to make sure you have enough red blood cells, white blood cells, and platelets. These tests help researchers understand your overall health status before you begin a trial.[10]

Imaging tests such as CT scans, MRI scans, or specialized PET scans are used to precisely measure the size and location of your tumors before starting a clinical trial. These baseline measurements are critical because researchers need to be able to compare how your tumors respond to the experimental treatment over time. Follow-up scans are performed at regular intervals during the trial to see if tumors are shrinking, staying the same size, or growing.[10]

Tissue samples from your biopsy may need to be tested for specific biomarkers, which are biological characteristics of the tumor cells. Some clinical trials are designed for patients whose tumors have certain genetic changes or express particular proteins on their surface. For example, trials might require that your tumor cells have somatostatin receptors or specific genetic mutations. These biomarker tests help match patients to the treatments most likely to benefit them.[4]

The stage of your cancer—meaning how far it has spread—is also important for clinical trial eligibility. Some trials are designed for patients with cancer that is confined to one area and can potentially be removed with surgery, while others are specifically for patients whose cancer has spread to multiple organs. Doctors use imaging tests and sometimes surgical exploration to accurately determine the stage of your disease.[10]

Performance status is another factor considered for clinical trials. This refers to how well you are able to carry out daily activities. Doctors assess whether you are active and able to do most things on your own, or whether you need significant help with daily tasks. Most clinical trials require that participants are well enough to tolerate the experimental treatment being studied.[14]

Prognosis and Survival Rate

Prognosis

The outlook for people with neuroendocrine carcinoma varies considerably depending on several important factors. The type of neuroendocrine cancer you have—whether it’s a slower-growing tumor or a fast-growing carcinoma—significantly affects your prognosis. Neuroendocrine carcinomas, which are high-grade and poorly differentiated, tend to be more aggressive than neuroendocrine tumors.[6]

Where the cancer started in your body and whether it has spread also impact your outlook. Some neuroendocrine cancers grow slowly and can be controlled for many years, even when they have spread to other parts of the body. Others grow more quickly and require more aggressive treatment. How well you respond to treatment is another key factor that influences prognosis.[8]

When caught at an early stage and the tumor can be completely removed with surgery, many patients can be cured. However, even after successful surgery, patients need to be followed for at least ten years to ensure the cancer doesn’t return. Unfortunately, many patients are diagnosed later when the cancer has already spread, making surgical cure less likely. Even in these cases, the disease and its symptoms can often be controlled for many years with appropriate treatment.[8]

Survival Rate

Early diagnosis and treatment continue to increase the number of people living for years with neuroendocrine cancer. Improved diagnostic tests that identify these cancers more quickly have contributed to better outcomes. Although neuroendocrine carcinomas are aggressive, advances in treatment options mean that many patients can live longer and maintain a good quality of life.[2]

It’s important to understand that survival statistics are general estimates and cannot predict exactly what will happen to any individual person. Many different factors influence how long someone lives with neuroendocrine carcinoma, including the specific characteristics of the cancer, how it responds to treatment, overall health, and age. The best person to discuss your individual prognosis is your own doctor, who knows all the details of your specific situation.[2]

Ongoing Clinical Trials on Neuroendocrine carcinoma

  • Study of Tarlatamab for Patients with Metastatic or Advanced Small-Cell Lung Cancer and Neuroendocrine Carcinomas

    Recruiting

    1 1
    Investigated drugs:
    France Germany
  • Study on Enfortumab Vedotin for Patients with Advanced Neuroendocrine Carcinoma Not Responding to or Ineligible for Platinum Chemotherapy

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain
  • Study of 64Cu-DOTATATE and 18F-FDG PET/CT imaging to predict disease progression in patients with neuroendocrine neoplasms

    Recruiting

    1 1 1
    Denmark
  • Study of Combined Imaging with Hyperpolarized [1-13C]Pyruvate and Fludeoxyglucose (18F) for Cancer Detection in Patients with Breast Cancer, Neuroendocrine Tumors, Lymphomas, or Sarcomas

    Recruiting

    1 1 1
    Denmark
  • Study of daily low-dose Temozolomide in patients with advanced neuroendocrine tumors (NETs) who are not eligible for standard treatments due to their health condition

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy
  • Study on BI 764532 for Patients with Relapsed or Refractory Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

    Recruiting

    1 1
    Belgium Bulgaria France Germany Italy Poland +2
  • Study Comparing FOLFIRINOX and Cisplatin-Etoposide for Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma

    Recruiting

    1 1 1
    Investigated diseases:
    France
  • Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Austria Belgium Czechia Denmark Finland France +8
  • Study of Tarlatamab alone or with FOLFIRI chemotherapy for patients with advanced digestive system or unknown origin neuroendocrine carcinomas

    Not recruiting

    1 1 1
    Investigated diseases:
    France Spain
  • Study of Cabozantinib and Avelumab for Patients with Advanced Neuroendocrine Tumors G3 Resistant to Standard Chemotherapy

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

References

https://www.mayoclinic.org/diseases-conditions/neuroendocrine-tumors/symptoms-causes/syc-20354132

https://my.clevelandclinic.org/health/diseases/22006-neuroendocrine-tumors-net

https://www.upmc.com/services/endocrinology/conditions/neuroendocrine-carcinomas

https://www.mdanderson.org/cancerwise/neuroendocrine-tumors–9-things-to-know.h00-159379578.html

https://pmc.ncbi.nlm.nih.gov/articles/PMC10420169/

https://www.cancerresearchuk.org/about-cancer/neuroendocrine-tumours-nets/what-are-nets

https://www.neuroendocrinecancer.org.uk/neuroendocrine-cancer/understanding-neuroendocrine-cancer/

https://neuroendocrine.org.au/what-are-nets/

https://en.wikipedia.org/wiki/Neuroendocrine_tumor

https://www.mayoclinic.org/diseases-conditions/neuroendocrine-tumors/diagnosis-treatment/drc-20465865

https://www.mdanderson.org/cancer-types/neuroendocrine-tumors/neuroendocrine-tumor-treatment.html

https://my.clevelandclinic.org/health/diseases/22006-neuroendocrine-tumors-net

https://www.cancerresearchuk.org/about-cancer/neuroendocrine-tumours-nets/treatment

https://winshipcancer.emory.edu/cancer-types-and-treatments/neuroendocrine-tumors/treatment.php

https://www.fredhutch.org/en/diseases/neuroendocrine-tumors/treatment.html

https://www.neuroendocrinecancer.org.uk/neuroendocrine-cancer/living-with-neuroendocrine-cancer/

https://netrf.org/old-for-patients/living-with-nets/symptom-management/

https://www.cancerresearchuk.org/about-cancer/neuroendocrine-tumours-nets/living-with/coping

https://www.uchicagomedicine.org/forefront/cancer-articles/2023/september/pancreatic-nets-patient-chris-meyer

https://www.webmd.com/cancer/features/neuroendocrine-tumors-self-care

https://www.rockymountaincancercenters.com/neuroendocrine-tumors/navigating-the-patient-journey

https://medlineplus.gov/diagnostictests.html

https://www.questdiagnostics.com/

https://www.healthdirect.gov.au/diagnostic-tests

https://www.who.int/health-topics/diagnostics

https://www.yalemedicine.org/clinical-keywords/diagnostic-testsprocedures

https://www.nibib.nih.gov/science-education/science-topics/rapid-diagnostics

https://www.health.harvard.edu/diagnostic-tests-and-medical-procedures

https://www.roche.com/stories/terminology-in-diagnostics

FAQ

What is the difference between a neuroendocrine tumor and a neuroendocrine carcinoma?

Neuroendocrine tumors can be slow, moderate, or fast growing, and their cells still look somewhat similar to normal neuroendocrine cells. Neuroendocrine carcinomas are all fast growing, and their cells look very abnormal and different from normal cells. This distinction is critical because they behave differently and require different treatment approaches.[6]

How long does it take to get a diagnosis of neuroendocrine carcinoma?

The timeline varies depending on your symptoms and which tests are needed. Often, neuroendocrine tumors grow slowly and may be present in your body for years before causing symptoms. Once you see a doctor, the diagnostic process typically includes blood tests, imaging scans, and a biopsy. Getting all results and a confirmed diagnosis may take several weeks.[3]

Is a biopsy always necessary to diagnose neuroendocrine carcinoma?

Yes, a biopsy is the most definitive way to diagnose neuroendocrine carcinoma. While blood tests and imaging can suggest the presence of a tumor, only examining tissue under a microscope can confirm whether cancer cells are present and determine the specific type of neuroendocrine cancer you have.[10]

What is a somatostatin receptor PET scan?

A somatostatin receptor PET scan, also called a dotatate PET scan, is a specialized imaging test that uses a radioactive tracer to find neuroendocrine tumors throughout the body. The tracer attaches to receptors that neuroendocrine tumor cells often have on their surface, making even small tumors visible on the scan.[10]

Can neuroendocrine carcinoma be detected with regular blood tests?

Regular blood tests may show clues such as anemia or elevated liver enzymes that prompt further investigation, but they cannot definitively diagnose neuroendocrine carcinoma. Specialized blood and urine tests that measure hormone levels, combined with imaging and biopsy, are needed for a confirmed diagnosis.[3]

🎯 Key Takeaways

  • Neuroendocrine carcinomas are rare cancers that often hide for years before causing symptoms, making persistent unexplained symptoms worth investigating.
  • The specialized dotatate PET scan can detect tiny neuroendocrine tumors throughout the entire body that other imaging tests might miss completely.
  • Knowing whether you have a neuroendocrine tumor or carcinoma is absolutely critical—they’re treated completely differently despite starting in the same cells.
  • A biopsy examined by a pathologist is the only definitive way to confirm neuroendocrine carcinoma and determine how aggressive your specific cancer is.
  • Blood and urine tests can reveal excess hormones produced by tumors, providing important clues about where the cancer is located in your body.
  • Clinical trials often require specific biomarker tests on your tumor tissue to match you with treatments most likely to work for your individual cancer.
  • When caught early enough for complete surgical removal, many neuroendocrine cancers can be cured, though long-term monitoring is essential.
  • Even when cancer has spread and cure isn’t possible, the disease can often be controlled for many years with modern treatments.